BRIEF-Zai Lab Receives U.S. FDA Fast Track Designation For Zl-1310, A Dll3-Targeted Antibody-Drug Conjugate, For Treatment Of Extensive-Stage Small Cell Lung Cancer

Reuters

May 19

May 19 (Reuters) - Zai Lab Ltd 9688.HK:

ZAI LAB RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR ZL-1310, A DLL3-TARGETED ANTIBODY-DRUG CONJUGATE, FOR TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER
ZAI LAB LTD - TO INITIATE PIVOTAL STUDY FOR ZL-1310 IN 2025

Source text: ID:nBw5PTTCha

Further company coverage: 9688.HK

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2536368634"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2536368634\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2536368634?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-19 19:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2536368634","market":"us","top_or_hot":-1,"title":"BRIEF-Zai Lab Receives U.S. FDA Fast Track Designation For Zl-1310, A Dll3-Targeted Antibody-Drug Conjugate, For Treatment Of Extensive-Stage Small Cell Lung Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Zai Lab Receives U.S. FDA Fast Track Designation For Zl-1310, A Dll3-Targeted Antibody-Drug Conjugate, For Treatment Of Extensive-Stage Small Cell Lung Cancer</title></head><body><p><span>May 19 (Reuters)</span><span> - </span>Zai Lab Ltd <span>9688.HK</span>:</p><ul><li><p>ZAI LAB RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR ZL-1310, A DLL3-TARGETED ANTIBODY-DRUG CONJUGATE, FOR TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER</p></li><li><p>ZAI LAB LTD - TO INITIATE PIVOTAL STUDY FOR ZL-1310 IN 2025</p></li></ul><p>Source text: <span>ID:nBw5PTTCha</span></p><p>Further company coverage: <span>9688.HK</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Zai Lab Receives U.S. FDA Fast Track Designation For Zl-1310, A Dll3-Targeted Antibody-Drug Conjugate, For Treatment Of Extensive-Stage Small Cell Lung Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Zai Lab Receives U.S. FDA Fast Track Designation For Zl-1310, A Dll3-Targeted Antibody-Drug Conjugate, For Treatment Of Extensive-Stage Small Cell Lung Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-19 19:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Zai Lab Receives U.S. FDA Fast Track Designation For Zl-1310, A Dll3-Targeted Antibody-Drug Conjugate, For Treatment Of Extensive-Stage Small Cell Lung Cancer</title></head><body><p><span>May 19 (Reuters)</span><span> - </span>Zai Lab Ltd <span>9688.HK</span>:</p><ul><li><p>ZAI LAB RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR ZL-1310, A DLL3-TARGETED ANTIBODY-DRUG CONJUGATE, FOR TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER</p></li><li><p>ZAI LAB LTD - TO INITIATE PIVOTAL STUDY FOR ZL-1310 IN 2025</p></li></ul><p>Source text: <span>ID:nBw5PTTCha</span></p><p>Further company coverage: <span>9688.HK</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09688","symbol_name":"再鼎医药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250519:nTUABRNFTM:1","article_id":"2536368634","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2536368634","pubTimestamp":1747654082,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Zai Lab Receives U.S. FDA Fast Track Designation For Zl-1310, A Dll3-Targeted Antibody-Drug Conjugate, For Treatment Of Extensive-Stage Small Cell Lung CancerMay 19 (Reuters) - Zai Lab Ltd 9688.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09688":"再鼎医药","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK1161":"生物科技","BK1588":"回港中概股","BK1574":"生物医药B类股"},"translate_title":"BRIEF-再鼎医药获得美国FDA快速通道指定，Zl-1310是一种靶向Dll3的抗体药物偶联物，用于治疗广泛期小细胞肺癌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09688":0.9},"content_text":"BRIEF-Zai Lab Receives U.S. FDA Fast Track Designation For Zl-1310, A Dll3-Targeted Antibody-Drug Conjugate, For Treatment Of Extensive-Stage Small Cell Lung CancerMay 19 (Reuters) - Zai Lab Ltd 9688.HK:ZAI LAB RECEIVES U.S. FDA FAST TRACK DESIGNATION FOR ZL-1310, A DLL3-TARGETED ANTIBODY-DRUG CONJUGATE, FOR TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCERZAI LAB LTD - TO INITIATE PIVOTAL STUDY FOR ZL-1310 IN 2025Source text: ID:nBw5PTTChaFurther company coverage: 9688.HK ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}